Skip to main content
ChengDa Pharmaceuticals Co.,Ltd. logo

ChengDa Pharmaceuticals Co.,Ltd. — Investor Relations & Filings

Ticker · 301201 ISIN · CNE100005766 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 455 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301201

About ChengDa Pharmaceuticals Co.,Ltd.

https://www.chengdapharm.com

ChengDa Pharmaceuticals Co., Ltd. specializes in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company maintains a diverse product portfolio with a significant focus on the L-carnitine series, including levocarnitine and its derivatives, serving as a major global supplier. Its therapeutic areas of expertise encompass cardiovascular health, metabolic disorders, and anti-infective treatments. ChengDa Pharmaceuticals operates advanced production facilities that adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications from regulatory bodies such as the FDA and EDQM. The organization emphasizes technological innovation and process optimization to provide high-purity chemical components for the global market, supporting both generic and proprietary drug development.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the resolutions passed at the 2025 Annual General Meeting, detailing voting procedures, attendance, and precise voting results on each proposal, along with legal opinions. It constitutes a declaration of voting results at a general meeting rather than the meeting materials themselves or any other category. Therefore, it matches Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-20 Chinese
国浩律师（上海）事务所关于诚达药业股份有限公司2025年年度股东会之见证法律意见书
Regulatory Filings Classification · 92% confidence The document is a legal opinion letter (“见证法律意见书”) issued by a law firm regarding the legality of convening, attending, and voting procedures at the company’s 2025 Annual General Meeting of Shareholders. It does not provide financial statements, earnings data, or investment analyses, nor is it a proxy solicitation or voting result announcement. Instead, it is a compliance/legal document required for the AGM. As there is no specific category for legal opinion letters, it falls into the fallback “Regulatory Filings” category for miscellaneous compliance documents (RNS).
2026-05-20 Chinese
光大证券股份有限公司关于诚达药业股份有限公司2025年年度跟踪报告
Regulatory Filings Classification · 82% confidence The document is a sponsor’s annual tracking report (‘年度跟踪报告’) prepared by 光大证券 for 诚达药业, summarizing sponsor review work, company performance, compliance checks, and related oversight measures. It is not an AGM presentation, earnings release, financial statements (full or interim), or any other specialized filing category. It constitutes a regulatory compliance report by the sponsor, serving as a miscellaneous regulatory filing. Under our taxonomy, it maps to the fallback category “Regulatory Filings (RNS).”
2026-05-15 Chinese
光大证券股份有限公司关于诚达药业股份有限公司首次公开发行股票并在创业板上市之持续督导保荐总结报告书
Regulatory Filings Classification · 93% confidence The document is a continuous supervision summary report (‘持续督导保荐总结报告书’) prepared by the sponsor (Guangda Securities) after the end of the IPO supervision period. It is not a financial statement, earnings release, or investor presentation, but a compliance report required by regulatory rules. There is no more specific category for a sponsor’s supervision report in the taxonomy, so it falls into the general Regulatory Filings (RNS) category as a compliance document.
2026-05-15 Chinese
关于举办2025年度业绩说明会的公告
Regulatory Filings Classification · 65% confidence The document is a formal announcement by the company of an upcoming 2025 earnings explanation meeting (“业绩说明会”), providing details on date, format, participants, and Q&A arrangements. It does not contain financial statements or substantive earnings data itself (so it is not an Interim/Quarterly Report or Annual Report), nor is it the actual presentation or slide deck (so it is not an Investor Presentation). It also is not an earnings release (no summary financial highlights), nor a transcript, nor a voting or governance item. As it is a general regulatory announcement of an investor event not covered by other specific categories, it falls into the fallback “Regulatory Filings” category (RNS).
2026-05-14 Chinese
关于持股5%以上股东减持股份的预披露公告
Major Shareholding Notification Classification · 85% confidence The document is a formal pre-disclosure announcement by a shareholder holding more than 5% describing a planned share reduction (number of shares, timing, regulatory framework, risk factors). This is not a company share buyback (POS) nor a financial report or dividend notice. It is a notification of a significant shareholder’s change in share ownership level, fitting the “Major Shareholding Notification” category (MRQ).
2026-05-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.